Celavie Biosciences, LLC, a company working to improve lives and restore hope by advancing innovations in CNS diseases with regenerative stem cell-based therapies, today announced their presentation of a poster, titled “Five year follow-up on the first-in-human transplantation of undifferentiated stem cells into Parkinsonian patients reveals no adverse effects with improvement in motor function or arrest of the disease progression in five out of seven patients,”
The poster shows five-year follow-up data that expands on the exploratory clinical data in 7 PD patients with four-year follow-up published in Cell Transplantation in 2018. Oleg Kopyov, Executive Vice President and Chief Scientific Officer at Celavie, presented the poster on-site at the Miami Hyatt Regency.
In the results at one year after cell grafting, all but two of the seven patients completing the study showed various degrees of motor improvement, and five of them showed better response to medication. At five-year evaluation, Unified Parkinson’s Disease Rating Scale III (UPDRS III) scores remained better than at baseline in 4/7 patients in the OFF condition and in 5/7 patients in the ON condition. None of the patients showed unwanted motor disturbances (dyskinesias), tumor formation, or any detectable immune responses to the grafted cells.
“We are excited that the five-year data for our exploratory clinical trial suggest that the neural progenitor cells are able to stop or slow down the motor deterioration in Parkinson’s patients that one would expect to see in this timespan, showing continued improvement even compared to the fourth year,” said Oleg Kopyov. “We anticipate filing an IND with the FDA for a Phase I U.S. trial in patients with moderate to advanced Parkinson’s disease this year.”
In addition, Sandy Solmon, Celavie’s CEO, will deliver presentations at two upcoming international industry conferences:
- BIO CEO & Investor Conference, held February 10-11 in New York, NY
- Cell & Gene Meeting on the Mediterranean, held April 15-17 in Barcelona, Spain
Ms. Solmon will discuss Celavie’s application of the company’s human undifferentiated allogeneic pluripotent stem cells in Parkinson’s disease, as well as pre-clinical data in cerebellar ataxia and upcoming milestones. To schedule a meeting with Celavie Biosciences at these conferences, please contact: Mary Beth Cicero at mbcicero@lavoiehealthscience.com.
About the World Stem Cell Summit
Produced by the non-profit Regenerative Medicine Foundation (RMF), and in its 15th year, the World Stem Cell Summit will take place January 21-24, 2020, in Miami, Florida in partnership with Phacilitate Leaders World, as part of Advanced Therapies Week. The Summit is the most inclusive and expansive interdisciplinary, networking, and partnering meeting in the stem cell science and regenerative medicine field. With the overarching purpose of fostering translation of biomedical research, funding, and investments targeting cures, the Summit and co-located conferences serve a diverse ecosystem of stakeholders. For more information about the upcoming World Stem Cell Summit in Miami, please visit: www.worldstemcellsummit.com.
About Celavie Biosciences
Celavie Biosciences is a privately-held company whose mission is to improve lives and restore hope by advancing regenerative stem cell therapies for the treatment of Parkinson’s disease and other disorders of the central nervous system (CNS). The company develops undifferentiated, unmodified allogeneic pluripotent stem cell-based therapies, holds a strong IP portfolio, including 18 issued patents, and has an experienced management team blending expertise in concept and cell technology, product scalability and entrepreneurship. Celavet, a subsidiary, applies the same proprietary technologies for the treatment and prevention of serious veterinary diseases. More information is available at https://www.celavie.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200122005497/en/
Source: Celavie Biosciences, LLC
View this news release online at:
http://www.businesswire.com/news/home/20200122005497/en
